ImmunityBio, Inc. IBRX Net margin
Net margin at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on trailing twelve months.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s net margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s net margin?
- ImmunityBio, Inc. (IBRX) reported net margin of -606.2% in Q1 2026.
- How has ImmunityBio, Inc.'s net margin changed year-over-year?
- ImmunityBio, Inc.'s net margin increased by 53.7% year-over-year, from -1,310.3% to -606.2%.
- What is the long-term trend for ImmunityBio, Inc.'s net margin?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s net margin has grown at a -58.1% compound annual growth rate (CAGR), from -24,089.5% to -310.2%.
- What does net margin mean?
- The share of every sales dollar that becomes bottom-line profit.
- How do you interpret net margin?
- Higher is better, but net margin mixes operating performance with financing and tax effects and one-off items — read it alongside operating margin to separate the operating story from the rest.
- How does net margin compare across companies?
- Comparable across peers but sensitive to leverage and tax structure; two operationally identical firms can show different net margins purely from financing.